Goldman initiated coverage on AbCellera Biologics with a new price target
$ABCL
Pharmaceuticals and Biotechnology
Health Care
Goldman initiated coverage of AbCellera Biologics with a rating of Buy and set a new price target of $30.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/7/2025 | $5.00 | Outperform | Leerink Partners |
| 8/20/2024 | Buy → Hold | The Benchmark Company | |
| 2/22/2024 | $9.00 | Hold → Buy | The Benchmark Company |
| 12/5/2023 | $6.00 | Overweight | KeyBanc Capital Markets |
| 11/6/2023 | Buy → Hold | The Benchmark Company | |
| 10/13/2023 | $20.00 | Overweight | Piper Sandler |
| 2/28/2023 | Outperform | Cowen | |
| 12/15/2022 | $30.00 | Buy | Goldman |
Leerink Partners resumed coverage of AbCellera Biologics with a rating of Outperform and set a new price target of $5.00
The Benchmark Company downgraded AbCellera Biologics from Buy to Hold
The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00
AbCellera (NASDAQ:ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology
ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. The Phase 1 study is anticipated to begin in Q3 of 2025 and will evalu
AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor (NK3R) that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. "Vasomotor symptoms of menopause affect millions of women, with significant impacts on their well-being, and their personal and professional lives," said Natalya Nazarenko, MD, Executive Medical Director at AbCel
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
8-K - AbCellera Biologics Inc. (0001703057) (Filer)
8-K - AbCellera Biologics Inc. (0001703057) (Filer)
8-K - AbCellera Biologics Inc. (0001703057) (Filer)
AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir
TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev
AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d
AbCellera (NASDAQ:ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology
AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause. ABCL635 is positioned as a next-generation neurokinin 3 receptor (NK3R) antagonist with an improved safety profile and convenient dosing regimen. If successful, we believe it has the potential to be a highly differentiated product in a large and established market," said Carl Hansen, P
AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)